by The U.S. sucralfate market is primarily driven by the increasing prevalence of gastrointestinal disorders. Sucralfate is a medication that forms an acidic barrier over ulcers in the stomach and intestine, protecting the ulcer from further damage by acid and pepsin. It is widely used to treat conditions like peptic ulcers, gastroesophageal reflux disease (GERD), and stress ulcers. Rising cases of gastrointestinal issues among the geriatric population as well as lifestyle disorders like obesity are fueling sucralfate demand. Additionally, sucralfate is generally well-tolerated with minor side effects and does not require monitoring of blood levels making it a preferred option for long term treatment of GI issues.
The Global U.S. Sucralfate Market Demand is estimated to be valued at US$ 70.05 Mn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the U.S. sucralfate market are Pfizer Inc.,Merck & Co., Inc.,GlaxoSmithKline plc,Novartis AG,Sanofi S.A.,Johnson & Johnson,Abbott Laboratories,Eli Lilly and Company,AstraZeneca plc,Bayer AG,Bristol-Myers Squibb Company,Roche Holding AG,Teva Pharmaceutical Industries Ltd.,Mylan N.V.,Allergan plc. These companies collectively hold major share of the market and are focused on expanding their sucralfate product portfolio as well as market presence through various inorganic and organic strategies like collaborations, mergers, and new product launches.
The key growing demand for sucralfate in the U.S. market is contributed by its increasing application in treatment of various gastrointestinal diseases and disorders which have high prevalence especially among geriatric population. Gastrointestinal issues like gastric ulcer, duodenal ulcer and gastroesophageal reflux disease (GERD) pose major healthcare burden and growing caseload of these disorders is a major factor driving sucralfate demand.
The technological advancements in sucralfate drug delivery systems is another factor expected to contribute significantly to the market growth. Companies are investing in development of novel drug formulations like chewable tablets, suspensions etc to improve patient compliance. Special formulations targeting pediatric patients are also in the development phase.
Market Trends
Some of the key trends being observed in the U.S. Sucralfate market include growing preference towards sucralfate among physicians due to its minor side effects as compared to proton pump inhibitors. This is contributing to higher prescription rates supporting market revenues. Additionally, sucralfate is available generically at lower cost than other gastroprotective drugs making it an affordable treatment option for gastric issues, thereby positively impacting its adoption.
Another trend is the increasing collaborations between drug makers and research organizations for clinical trials evaluating sucralfate effectiveness in new indications like management of digestive issues in chemotherapy patients. Positive clinical outcomes can potentially open avenues for label expansion of sucralfate products.
Market Opportunities
The opportunities in the U.S. Sucralfate market lie in development of novel drug delivery systems like orally disintegrating tablets and chewable/liquid formulations which can drive patient compliance especially for pediatric use. Targeted formulations with modified release properties promising once or twice daily dosing can gain popularity.
Secondly, clinical evaluations assessing sucralfate usage in ailments like ulcerative colitis where current treatment options provide limited relief can lead to label expansion and open new revenue streams. This indicates potential for sucralfate to garner increased usage if effective management of broader gastrointestinal disorders is proven.
Impact of COVID-19 on U.S. Sucralfate Market
The COVID-19 pandemic has impacted the growth of the U.S. sucralfate market. Disruptions in manufacturing and supply chain operations, trade restrictions, lockdowns and travel bans implemented to control the spread of virus have severely affected the production and distribution of sucralfate drugs in the country. This led to shortage of sucralfate products in the market during the initial months of pandemic. Delayed surgeries and decline in hospital visits also contributed to reduced demand for sucralfate from hospitals and clinics. However, with easing of restrictions and resumption of business activities from mid-2020, the supply chain issues have been resolved to some extent and sucralfate production is back on track. The companies are also ramping up production capacity to cope up with the pending demand. It is expected that the market will witness steady growth from 2021 onwards as healthcare facilities gradually normalize their operations. The long term outlook for sucralfate market remains positive with increasing investment in development of new drugs and approval of sucralfate for new indications.
Geographical Concentration of U.S. Sucralfate Market
In terms of value, Northeast region accounts for the largest share in the U.S. sucralfate market currently. This is attributed to high density of healthcare facilities and major market players based in states like New York, New Jersey, Pennsylvania and Massachusetts. The region is also an early adopter of new drugs and therapies. Midwest region holds the second largest market share owing to significant generic drug manufacturing presence and growing patient population. Southern states like Texas, Florida and North Carolina are emerging as high growth regions due to expanding healthcare infrastructure and services. West coast states in particular California represents another lucrative market for sucralfate sales.
Fastest Growing Region for U.S. Sucralfate Market
The Southern region is poised to witness fastest growth in the U.S. sucralfate market during the forecast period. This is attributed to rising healthcare expenditure, robust economic growth, increasing patient insurance coverage under Medicaid expansion and ageing population susceptible to gastric ulcers in this region. Further, growing prominence of ambulatory surgery centers as low cost alternative to hospitals is driving the demand for sucralfate from these facilities. Additionally, strategic expansions by market players through new production plants and collaborative deals with regional healthcare providers are supporting the market growth in Southern states.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
